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Background: Neprilysin (NEP) inhibition increases natriuretic peptides, potentially providing beneficial cardiovascular and renal effects. LCZ696 is 
a first-in-class, dual-acting angiotensin receptor NEP inhibitor (ARNi) that delivers angiotensin blockade and NEP inhibition via valsartan (VAL) and 
AHU377 moieties, respectively.
Methods: The primary objective of this study was to assess LCZ696 for superiority in lowering blood pressure (BP) compared with VAL. After 4 weeks 
of washout/placebo run-in, 1328 eligible patients with mild-to-moderate hypertension were randomized to LCZ696 400 mg, 200 mg or 100 mg; VAL 
320 mg, 160 mg or 80 mg (similar VAL doses to LCZ696 based on area under the concentration curve); AHU377 200 mg; or placebo for an 8-week 
treatment period.
Results: LCZ696 400 mg and 200 mg reduced mean sitting systolic BP and diastolic BP (SBP/DBP) by an additional 6/3 and 5/3 mmHg 
compared with VAL 320 and 160 mg, respectively (Table 1). 24-hour ambulatory BP monitoring (n = 427) results were consistent with office BPs. 
Pulse pressure was also lowered to a greater extent with LCZ696 400 mg and 200 mg than respective VAL groups (both P < 0.05). LCZ696 was well 
tolerated, and had a similar safety and tolerability profile as VAL and placebo.
Conclusions: These results demonstrate that NEP inhibition contributes to the efficacy of LCZ696 and that ARNi acts via two complementary 
mechanisms. LCZ696 may represent an attractive therapeutic approach for the treatment of various cardiovascular disorders.
Table 1. Least squares mean (SE) change from baseline to week 8 in SBP and DBP
LCZ696 400 mg
(n = 170)
LCZ696 200 mg
(n = 168)
LCZ696 100 mg
(n = 154)
Valsartan
320 mg
(n = 163)
Valsartan
160 mg
(n = 163)
Valsartan
80 mg
(n = 163)
AHU377
200 mg
(n = 164)
Placebo
(n = 172)
SBP (mmHg) 
−20.2
(1.1)*#
−18.7 (1.1)*# −13.8 (1.2)# −14.2 (1.1)# −13.4 (1.1)# −12.4 (1.1)# −11.9 (1.1)#
−7.7
(1.1)
DBP (mmHg) −13.6 (0.7)*# −12.9 (0.7)*# −10.0 (0.7)# −10.9 (0.7)# −10.0 (0.7)#
−9.1
(0.7)#
−9.8
(0.7)#
−6.8
(0.7)
*P < 0.01, LCZ696 400 mg vs VAL 320 mg and LCZ696 200 mg vs VAL 160 mg; #P < 0.01 vs placebo
